BSX trades above its 50‑day and 200‑day moving averages with a healthy cash‑flow conversion, supporting a tighter valuation multiple. The recent recall has been priced in, leaving upside potential if execution improves.

Investor sentiment remains upbeat, buoyed by neurostimulation growth and a recent price rally that outperformed the sector. The recall is viewed as a short‑term blemish rather than a systemic issue.

While the catheter recall and execution risk modestly elevate downside uncertainty, BSX’s long‑term pipeline and market share gains in electrophysiology offset these concerns. The turnaround narrative remains credible, keeping a bullish outlook.

Technical indicators show a bullish MACD crossover, RSI around 55, and above‑average volume on up days, suggesting momentum remains intact. Price is consolidating near a key support level that aligns with its revised valuation.